Study on the morphology of spinal cord contusion injury rats by early treatment with erythropoietin

Abstract

Abstract: AIM: To study the morphological and behavior changes of spinal cord contusion rats by early treatment with erythropoietin(EPO). METHODS: Spinal cord contusion injury model in rats was duplicated with a Benchmark^TM stereotaxic cortical impactor. Posttraumatic 30 min, animals were administrated by 5000UI·kg^-1·BW recombinant human erythropoietin or equal volume of saline through intraperitoneal injection. The inclined plane test and BBB scale were used to assess the hindlimb motor function. Morphological changes were inspected by using the Harris HE staining method combining with Luxol fast blue staining and Nissl staining. Blood routine test and hemorheology were to monitor the effect of erythrocytic hyperplasia.RESULTS: With the increase in training days the angle sustaining on the inclined plane and BBB scores of EPO group were significantly higher than that of model group(P<0.05). Posttraumatic 7,14,28 days the cavity size of injured center and adjacent parts in EPO group were significantly reduced. The numbers of survival neuron in the bilateral anterior horn of gray matter at 3 mm, 5 mm rostral and candual to the injury site in EPO group were statistically more than those in model group (P<0.05). Posttraumatic 14 and 28 days the LFB-positive area at injured site and 3mm, 5mm rostral and candual to epicentre in EPO group were significantly higher than those in model group (P<0.05). After injury the red blood cell count, hemoglobin and hematocrit showed a clear gradual upward trend. From posttraumatic 14 days the whole blood low-shear viscosity, middle-shear viscosity significantly increased compared with the model group (P<0.05).CONCLUSION: Early treatment with EPO may promote neuronal survival and reduce the loss of myelin sheath to mitigate secondary damage, and ultimately improve the hindlimb motor function, but increased the risk of hematogenic adverse reactions.

Key words: Traumatic spinal cord injury, Erythropoietin, Motor function score, Neurons, Myelin

CLC Number:

GU Bing, WANG Shuo-yu, LI Hua-nan, WANG Jun, ZHANG Shui-yin. Study on the morphology of spinal cord contusion injury rats by early treatment with erythropoietin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 147-155.

References

[1] Baptiste DC,Fehlings MG.Pharmacological approaches to repair the injured spinal cord[J]. J Neurotrauma, 2006, 23(3/4): 318-334.
[2] Kubeck JP, Merola A, Mathur S, et al.End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model[J]. Spine (Phila Pa 1976), 2006, 31(3): 257-261.
[3] Carelli S, Marfia G, Di Giulio AM, et al.Erythropoietin: recent developments in the treatment of spinal cord injury[J]. Neurol Res Int, 2011: 453179.
[4] Mofidi A, Bader A, Pavlica S.The use of erythropoietin and its derivatives to treat spinal cord injury[J]. Mini Rev Med Chem, 2011, 11(9): 763-770.
[5] 顾兵,金建波,李华南,等. 大鼠创伤性脊髓损伤模型的建立[J]. 中国临床药理学与治疗学, 2011, 16(7): 721-728.
[6] 顾兵,王俊,李华南,等. 大剂量甲强龙冲击治疗大鼠脊髓挫伤的形态学研究[J]. 中国药理学通报, 2012, 28(10): 1417-1423.
[7] Oyinbo CA.Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade[J]. Acta Neurobiol Exp (Wars), 2011, 71(2): 281-299.
[8] Tehranipour M,Moghimi A.Neuroprotective effects of testosterone on regenerating spinal cord motoneurons in rats[J]. J Motor Behav, 2010, 42(3): 151-155.
[9] Joyeux-Faure M.Cellular protection by erythropoietin: new therapeutic implications[J] ? J Pharmacol Exp Ther, 2007, 323(3): 759-762.
[10] Grasso G, Sfacteria A, Cerami A, et al.Erythropoietin as a tissue- protective cytokine in brain injury: what do we know and where do we go[J]? Neuroscientist, 2004, 10(2): 93-98.
[11] Basso DM, Beattie MS, Bresnahan JC.MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability[J]. J Neurotrauma, 1996, 13(7): 343-359.
[12] Vitellaro-Zuccarello L, Mazzetti S, Madaschi L, et al.Chronic erythropoietin-mediated effects on the expression of astrocyte markers in a rat model of contusive spinal cord injury[J]. Neuroscience, 2008, 151(2): 452-466.
[13] Sirén AL, Fasshauer T, Bartels C, et al.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system[J]. Neurotherapeutics, 2009, 6(1): 108-127.
[14] Chang CM, Lee MH, Wang TC, et al.Brain protection by methylprednisolone in rats with spinal cord injury[J]. NeuroReport, 2009, 20(10): 968-972.
[15] Sakurai M, Hayashi T, Abe K, et al.Delayed and selective motor neuron death after transient spinal cord ischemia a role of apoptosis[J]? J Thorac Cardiovasc Surg, 1998, 115(6): 1310-1135.
[16] Smith PD, Puskas F, Fullerton DA, et al.Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin[J]. J Thorac Cardiovasc Surg, 2011, 141(1): 256-260.
[17] Ning B, Zhang A, Song H, et al.Recombinant human erythropoietin prevents motor neuron apoptosis in a rat model of cervical sub-acute spinal cord compression[J]. Neurosci Lett, 2011, 490(1): 57-62.
[18] Cetin A, Nas K, Büyükbayram H, et al.The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats[J]. Eur Spine J, 2006, 15(10): 1539-1544.
[19] McDonald JW,Belegu V. Demyelination and remyelination after spinal cord injury[J]. J Neurotrauma, 2006, 23(3/4): 345-359.
[20] Nashmi R,Jones OT,Fehlings MG.Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2 K+ channels after chronic spinal cord injury[J]. Eur J Neurosci, 2000, 12(2): 491-506.
[21] Pinzon A, Marcillo A, Quintana A, et al.A reassessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model[J]. Brain Res, 2008, 1243: 146-151.
[22] Okutan O, Solaroglu I, Beskonakli E, et al.Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats[J]. J Clin Neurosci, 2007, 14(4) : 364-368.
[23] Savino C, Pedotti R, Baggi F, et al.Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis[J]. J Neuroimmunol, 2006, 172(1/2) : 27-37.